Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$16.41 USD
-0.70 (-4.09%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.40 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.41 USD
-0.70 (-4.09%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.40 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Earnings Preview: Travere Therapeutics (TVTX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
by Zacks Equity Research
Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.
New Strong Sell Stocks for June 25th
by Zacks Equity Research
CVGW, KDNY, CMTL, GPL and TVTX have been added to the Zacks Rank #5 (Strong Sell) List on June 25, 2021.
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -71.43% and -5.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Travere Therapeutics (TVTX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere Therapeutics (TVTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -451.16% and -0.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
What's in the Cards for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio (INO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.
Why Earnings Season Could Be Great for Travere Therapeutics (TVTX)
by Zacks Equity Research
Travere Therapeutics (TVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Are Options Traders Betting on a Big Move in Travere Therapeutics (TVTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Travere Therapeutics (TVTX) stock based on the movements in the options market lately.
scPharmaceuticals (SCPH) Plunges on Complete Response Letter
by Zacks Equity Research
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult patients.
Reata (RETA) Omaveloxolone Program Faces Delay on FDA Update
by Zacks Equity Research
Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.